Cihan Tastan
Overview
Explore the profile of Cihan Tastan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ates A, Tastan C, Ermertcan S
CRISPR J
. 2024 Nov;
7(6):374-384.
PMID: 39514329
Antibiotic resistance poses a global health crisis limiting the efficacy of available therapeutic agents. We explored CRISPR-Cas-based antimicrobials to combat multidrug resistance in methicillin-resistant (MRSA), targeting methicillin (A), gentamicin (A),...
2.
Demir S, Tastan C, Omeroglu Ulu Z, Canbaz E, Unlen L, Sahin F
J Virol Methods
. 2024 Jul;
329:114994.
PMID: 38971379
Herpes Simplex Virus Type 1 (HSV-1) is a widespread human pathogen known for causing a spectrum of clinical manifestations, ranging from mild cold sores to severe complications like encephalitis. Understanding...
3.
Kose A, Kocadagli O, Tastan C, Aktan C, Unaldi O, Guzenge E, et al.
CRISPR J
. 2024 Jun;
7(3):168-178.
PMID: 38922052
The revolutionary CRISPR-Cas9 technology has revolutionized genetic engineering, and it holds immense potential for therapeutic interventions. However, the presence of off-target mutations and mismatch capacity poses significant challenges to its...
4.
Sert B, Gulden G, Teymur T, Ay Y, Turan R, Unaldi O, et al.
Cancer Gene Ther
. 2023 Dec;
31(3):387-396.
PMID: 38092962
Chimeric antigen receptor T (CAR-T) cell therapy holds great promise as an innovative immunotherapeutic approach for cancer treatment. To optimize the production and application of CAR-T cells, we evaluated the...
5.
Eren S, Tastan C, Karadeniz K, Turan R, Cakirsoy D, Kancagi D, et al.
Curr Gene Ther
. 2023 Apr;
23(4):304-315.
PMID: 37032509
Aim: Duchenne Muscular Dystrophy (DMD) results in a deficiency of dystrophin expression in patient muscle fibers, leading to progressive muscle degeneration. Treatment of DMD has undertaken current transformation with the...
6.
Hemsinlioglu C, Aslan E, Tastan C, Cakirsoy D, Turan R, Seyis U, et al.
Turk J Haematol
. 2023 Apr;
40(2):118-124.
PMID: 37022209
Objective: Hemophilia A is an X-linked recessive bleeding disorder caused by a deficiency of plasma coagulation factor VIII (FVIII), and it accounts for about 80%-85% of all cases of hemophilia....
7.
Gulden G, Sert B, Teymur T, Ay Y, Tiryaki N, Mishra A, et al.
Vaccines (Basel)
. 2023 Feb;
11(2).
PMID: 36851194
The development of genetic modification techniques has led to a new era in cancer treatments that have been limited to conventional treatments such as chemotherapy. intensive efforts are being performed...
8.
Erdogan E, Yalcin K, Hemsinlioglu C, Sezgin A, Seyis U, Kancagi D, et al.
Turk J Haematol
. 2022 Jul;
39(3):206-210.
PMID: 35848614
Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial...
9.
Turan R, Tastan C, Kancagi D, Yurtsever B, Sir Karakus G, Ozer S, et al.
Sci Rep
. 2021 Aug;
11(1):15799.
PMID: 34349145
The SARS-CoV-2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A and...
10.
Yenmis G, Sarac E, Besli N, Soydas T, Tastan C, Kancagi D, et al.
Acta Histochem
. 2021 Mar;
123(4):151709.
PMID: 33711726
Current evidence strongly suggests that aberrant activation of the nuclear factor kappa B (NF-kB) signaling cascade is connected to carcinogenesis. The matrix metalloproteinases (MMP) which are also the key agents...